Abstract
Purulent pericarditis caused by Nocardia, a rare opportunistic infection associated with a high mortality, is frequently misdiagnosed as Mycobacterium tuberculosis (MTB) or other bacterial infections. We report a case of Nocardia-induced purulent pericarditis in a patient with acquired immune deficiency syndrome (AIDS). The patient experienced multiple misdiagnoses and received inappropriate anti-tuberculosis therapy. Timely pericardial puncture and subsequent culture of the pericardial effusion identified Nocardia, prompting initiation of appropriate antibiotic therapy which led to clinical cure. This case report underscores the importance of broad differential diagnostic considerations in purulent pericarditis and emphasizes that prompt initiation of Nocardia-directed antibiotic therapy, guided by microbiological identification, is crucial for timely diagnosis and management. Additionally, we review and summarize previously reported cases of laboratory-confirmed Nocardia pericarditis in AIDS patients.
Background
Nocardia species are filamentous, partially acid-fast, aerobic, Gram-positive bacteria ubiquitous in soil and water (1). The skin, lungs, and brain are the most common sites of infection; however, disseminated disease can potentially affect any organ (–). Nocardia can infect a small minority of immunocompetent individuals (). Nocardia is primarily an opportunistic pathogen, with most cases reported in patients with acquired immune deficiency syndrome (AIDS) or other conditions impairing cell-mediated immunity, such as hematologic malignancies (leukemia, lymphoma), solid organ transplantation, and prolonged glucocorticoid therapy (, , ). Consequently, mortality is significantly influenced by these underlying risk factors ().
Nocardia pericarditis is a rare opportunistic infection characterized by high mortality and nonspecific symptoms. Due to similarities in staining characteristics (partially acid-fast) and morphology with Mycobacterium tuberculosis (MTB), nocardiosis is frequently misdiagnosed as tuberculosis (TB) (). This report describes an AIDS patient who developed Nocardia pericarditis.Despite experiencing multiple misdiagnoses and receiving inappropriate anti-tuberculosis therapy, timely pericardial puncture and effusion culture ultimately identified Nocardia. This led to the initiation of appropriate antibiotic therapy and subsequent clinical cure. We aim to emphasize the critical importance of considering Nocardia in the differential diagnosis of purulent pericarditis and the need for timely, targeted antibiotic therapy based on microbiological identification to facilitate effective management of Nocardia pericarditis. Additionally, we discuss previously reported cases of Nocardia pericarditis in AIDS patients.
Case presentation
A 52-year-old Chinese male presented with a chief complaint of fever, fatigue, and dyspnea persisting for two weeks. Based on the patient's immunocompromised status (recently diagnosed AIDS), exudative pericardial effusion, pericardial fluid adenosine deaminase (ADA) level >45 U/L [a biomarker with 98% positive predictive value for TB pericarditis in TB-endemic areas ()], elevated erythrocyte sedimentation rate (ESR), and positive MTB IgG serology (indicating prior TB exposure), he was initially diagnosed with tuberculous pericarditis (TBP). This diagnosis was made despite a negative IGRA result, which was interpreted in light of the known limitation of IGRA sensitivity in HIV-infected individuals ().
The patient underwent pericardial puncture with indwelling catheter placement for continuous drainage and received one week of anti-tuberculosis therapy for presumed TBP at a local hospital. However, his symptoms failed to improve, prompting transfer to our hospital for further management. He had a recent diagnosis of AIDS, with no prior CD4+ T-cell count monitoring or antiretroviral therapy (ART). No significant comorbidities, smoking history, or known drug allergies were reported. Vital signs on admission were: temperature 36.7 °C (post-antipyretic), blood pressure 109/84 mmHg, heart rate 107 beats/min, respiratory rate 22 breaths/min, and oxygen saturation 96% with supplemental oxygen at 2 L/min. Physical examination revealed bilateral diminished breath sounds, enlarged cardiac dullness (suggesting significant pericardial effusion), and bilateral pitting edema of the lower extremities. Purulent pericardial fluid drained continuously via the indwelling catheter. Laboratory results demonstrated a markedly reduced peripheral blood lymphocyte percentage of 3.3% (reference range: 20%–40%) alongside significantly elevated inflammatory markers: C-reactive protein (CRP) 146.34 mg/L (reference: <8.2 mg/L) and procalcitonin (PCT) 1.05 ng/ml (reference: <0.05 ng/ml). The IGRA returned negative. Peripheral blood lymphocyte subset analysis revealed profound depletion of CD3+ CD4+ T-cells (0.01%; reference range: 27%–51%) and complete inversion of the CD4+/CD8+ T-cell ratio (0.00), consistent with WHO Stage 3 HIV/AIDS (). Peripheral blood lymphocyte examination revealed increased peripheral blood B-cell percentage (46.58%; reference range: 5%–18%), indicative of HIV-associated polyclonal B-cell dysregulation. Serological testing was positive for MTB IgG antibody (TB-IgG), suggesting prior tuberculosis exposure. Chest CT scans revealed bilateral symmetric pleural effusions with localized atelectasis in the lower lobes of both lungs, and massive pericardial effusion (Figure 1A). Echocardiography confirmed a large pericardial effusion. Given the absence of neurological symptoms, cranial imaging was not performed.
Figure 1
Figure 2
Based on the initial assessment from the local hospital and subsequent diagnostic findings upon admission, the patient continued to receive anti-tuberculosis therapy. Despite this treatment, the patient's condition deteriorated, with progressive worsening of symptoms, hypotension (blood pressure 92/63 mmHg), and increased shortness of breath. Persistent large-volume drainage of viscous, purulent pericardial fluid via the indwelling catheter was noted. On the fourth day of hospitalization, laboratory findings revealed a severe acid-base disturbance (arterial blood pH 7.631), hypokalemia (serum potassium 2.90 mmol/L), and hypochloremia (serum chloride 83 mmol/L), culminating in metabolic alkalosis. The pathogenesis of these electrolyte imbalances was thought to be related to electrolyte losses associated with an underlying infection. Therapeutic interventions included aggressive intravenous repletion with potassium chloride and aggressive ventilation. Subsequent arterial blood gas analysis demonstrated that both pH and electrolyte levels were approaching normal. Given the absence of fibrotic changes on chest imaging, the differential diagnosis focused on inflammatory pericardial diseases causing pericardial effusion. The following conditions were considered and required exclusion: (1) Non-tuberculous mycobacterial (NTM) infection: This was considered less likely due to the absence of characteristic pulmonary lesions often associated with disseminated NTM disease in immunocompromised hosts. (2) TBP: This diagnosis became increasingly unlikely given the persistence of the patient's symptoms and purulent drainage despite ongoing anti-tuberculosis therapy. (3) Fungal pericarditis: While the negative serum 1,3-β-D-glucan (BDG) test argued against some fungal etiologies, it does not definitively exclude fungal infection. Empiric intravenous therapy with piperacillin/sulbactam (2.25 g every 12 h) was initiated due to disease progression and elevated inflammatory markers.
Fungal and routine bacterial cultures of blood and pericardial fluid, viral molecular testing, and pericardial fluid Xpert MTB/RIF assay (which excluded M. tuberculosis) were all negative. However, microscopic examination of the pericardial fluid revealed branching Gram-positive bacilli on Gram stain, which exhibited partial acid-fastness on modified Ziehl-Neelsen stain, suggesting possible Nocardia infection. The pericardial fluid was subjected to Gram staining (revealing branching Gram-positive bacilli), modified Ziehl–Neelsen staining (confirming partial acid-fastness), and prolonged aerobic culture on sheep blood agar at 37 °C for 10 days. This extended incubation period is critical to avoid false negatives in immunocompromised hosts (). Growth characteristics (dry, chalk-white colonies observed by day 7) and microscopic morphology confirmed the isolate as Nocardia genus. Species-level identification was not performed due to lack of access to MALDI-TOF mass spectrometry or 16S rRNA sequencing. Due to resource limitations that prevented species identification, therapy could not be optimized based on specific species susceptibility patterns. Literature indicates variable sulfonamide susceptibility among common pathogenic species like N. asteroides (–) complex and N. brasiliensis (). Therefore, broad-spectrum combination therapy was necessitated. Susceptibility testing demonstrated susceptibility to amikacin, amoxicillin/clavulanic acid, ceftriaxone, imipenem, ciprofloxacin, minocycline, and trimethoprim-sulfamethoxazole (TMP-SMZ). Antitubercular medications and piperacillin/sulbactam were discontinued, and combination therapy with intravenous ceftriaxone (4 g/day) plus intravenous amikacin (0.4 g/day) was initiated.
On hospital day 13, persistent drainage of thick, purulent exudate led to complete occlusion of the pericardiocentesis catheter. A repeat pericardiocentesis was performed with placement of a new drainage catheter. TMP-SMZ (trimethoprim 160 mg/sulfamethoxazole 800 mg twice daily) was added to the ongoing empirical antibacterial regimen of amikacin (0.4 g/day) and ceftriaxone (4 g/day). Subsequently, the patient demonstrated gradual symptomatic improvement accompanied by reduced pericardial fluid output.
However, drug-induced myelosuppression and hepatotoxicity developed during antimicrobial therapy, manifested as significant leukopenia (white blood cell nadir: 1.27 × 109/L), anemia (hemoglobin nadir: 61 g/L), and elevated transaminases. These adverse events were causally linked to high-dose ceftriaxone administration (4 g/day) and TMP-SMZ, consistent with the documented risks of myelosuppression and hepatotoxicity associated with this agent (–). Following subcutaneous recombinant human granulocyte colony-stimulating factor (rhG-CSF; 150 μg once daily) combined with intravenous glutathione (1.2 g daily) for hepatoprotection, leukocyte counts returned to normal range (6.39 × 109/L) and transaminase levels declined below the upper limit of normal (<40 U/L).
A chest CT scan prior to discharge showed significant resolution of the bilateral pleural and pericardial effusions (Figure 1B). Corresponding echocardiography indicated a small residual pericardial effusion. At outpatient follow-up, the patient received oral TMP-SMZ [trimethoprim 160 mg/sulfamethoxazole 800 mg (0.96 g) twice daily] combined with oral amoxicillin/clavulanic acid [0.686 g (e.g., amoxicillin 600 mg/clavulanic acid 86 mg) twice daily] for an additional six months. Subsequent follow-up visits revealed no recurrence of infectious symptoms and no severe adverse reactions to the antimicrobial regimen. Repeat chest CT scan and echocardiography showed complete resolution of the pericardial effusion with no evidence of residual fibrosis or calcification (Figures 1C,D). The clinical timeline of the patient's diagnosis, treatment, and adverse events is summarized in Figure 2.
Discussion and conclusions
While nocardiosis is uncommon in AIDS [incidence: 0.2%–1.8% ()], pericardial involvement is exceptionally rare. Our literature review (Table 1) reveals key trends: 81.8% male predominance (9/11 cases), 54.5% incidence of cardiac tamponade (6/11), and 27.3% mortality (3/11)—underscoring the virulence of this pathogen in immunocompromised hosts.
Table 1
| Age | Sex | cardiac tamponade | CD4 cell count (cells/mm3) | Misdiagnose tuberculous pericarditis | Drainage/surgery/drainage flow | Drug treatment | Antiretroviral therapy | Outcome | References |
|---|---|---|---|---|---|---|---|---|---|
| 32 | Male | No | 48 | No | Subxiphoid pericardiostomy (1,100 ml fluid) | SMX/TMP, IV | Not reported | Recovered | Holtzet al. () |
| 34 | Male | No | 66 | No | Pericardiostomy (400 ml fluid) | SMX/TMP, IV, 3 weeks | Not reported | Died | Holtzet al. () |
| 34 | Male | Yes | 239 | No | Pericardiostomy (400 ml fluid) | SMX/TMP, IV, 5 days → Sulfadiazine, PO, 3 months | Yes | Recovered | Rivero et al. () |
| 42 | Male | No | 91 | Yes | Pericardial window | SMX/TMP but allergy → Ceftriaxone + Minocycline, 6 weeks | Not reported | Recovered | Ramanathan and Rahimi () |
| 24 | Female | Yes | Not reported | No | Pericardial aspirations with indwelling catheter (900 ml fluid) | SMX/TMP, PO | Not reported | Recovered | Leang et al. () |
| 44 | Male | No | 42 | Yes | Pericardiocentesis followed by surgical drainage with pericardial window | SMX/TMP, IV → PO | No | Recovered | Jinno et al. () |
| 35 | Female | Yes | 32 | Yes | Pericardiocentesis (500 ml fluid) | SMX/TMP + ceftriaxone + doxycycline, IV → SMX/TMP + doxycycline, PO | Yes | Recovered | Chandrashekar et al. () |
| 37 | Male | Yes | 50 | No | Subxiphoid pericardial drain (800 ml fluid) | Imipenem/cilastatin + SMX/TMP, IV → SMX/TMP, PO | No | Recovered | Aisenberg and Martin () |
| 32 | Male | Yes | 17 | Yes | Emergency pericardiocentesis | Imipenem/cilastatin + SMX/TMP, IV | Yes | Died | Laksananun et al. (53) |
| 32 | Male | Yes | 4 | No | Pericardiocentesis | →SMX/TMP + Imipenem/cilastatin, IV, Continue anti-TB therapy (HREZ) | Not reported | Died | Griessel et al. (27) |
| 52 | Male | No | Not reported | No | pericardiocentesis with indwelling catheter (4,280 ml of pus) | SMZ/TMP, PO + ceftriaxone + Amikacin, IV → SMZ/TMP and amoxicillin/clavulanic acid, PO | No | Recovered | Xinxin Z et al. (current study) |
Summary of all published cases of nocardial pericarditis in AIDS.
AIDS, acquired immune deficiency syndrome; SMX/TMP, sulfamethoxazole/trimethoprim; IV, intravenous; PO, per oral; TB, tuberculosis; H, isoniazid; R, rifampin, Z, pyrazinamide; E, ethambutol.
The clinical presentation of Nocardia pericarditis is nonspecific. Common symptoms, as reported in the literature, include fever, night sweats, dyspnea, anorexia, weight loss, chest pain, chills, cough, and fatigue (, 27). Prior to microbiological confirmation, the clinical diagnosis of Nocardia pericarditis is challenging and requires differentiation from other causes of purulent pericarditis (Table 2).
Table 2
| Characteristics | Nocardial pericarditis (, 53) | Tuberculous pericarditis () | MRSA pericarditis (, ) | Viral pericarditis (Influenza—related) () | Fungal pericarditis (, ) |
|---|---|---|---|---|---|
| Susceptible Populations | Immunocompromised individuals (such as those with AIDS) | People in developing countries, HIV—infected individuals | Long—term hospitalized patients, those with chronic underlying diseases | All age groups, more common in men and the elderly | Severely immunosuppressed patients |
| Typical Symptoms | Fever, dyspnea, purulent pericardial effusion | Low—grade fever, night sweats, elevated adenosine deaminase | High fever, sepsis, cardiac tamponade | Chest pain, influenza—like symptoms, tachycardia | Fever, weight loss, elevated BDG |
| Gold Standard for Diagnosis | Pericardial effusion culture (should be extended to at least 10 days) | Xpert MTB/RIF | MRSA culture from pericardial effusion | Viral nucleic acid detection | Fungal culture/BDG detection |
| First—line Treatment | SMZ/TMP + ceftriaxone/amikacin | Combined anti—tuberculosis drug treatment | Vancomycin | Supportive treatment + antiviral drugs | Amphotericin B/echinocandins |
| Mortality Rate | 28.3% (in AIDS—complicated cases) | High (when not treated in a timely manner) | 20.5% (in adults) | Low (with timely treatment) | High (in immunosuppressed patients) |
Comparative characteristics of different etiologies of purulent pericarditis.
AIDS, acquired immune deficiency syndrome; SMX/TMP, sulfamethoxazole/trimethoprim; BDG, β-D-glucan; MRSA, methicillin-resistant Staphylococcus aureus.
In developing countries, TBP remains the predominant cause of purulent pericarditis (). Mycobacterium tuberculosis can disseminate to the pericardium via retrograde lymphatic spread, hematogenous dissemination, or direct extension from adjacent lung, pleural, or spinal foci (). In patients co-infected with HIV, pericardial effusion cultures are positive for MTB in only approximately 35% of TBP cases (). Xpert MTB/RIF and Xpert MTB/RIF Ultra are automated, cartridge-based nucleic acid amplification tests (NAATs) capable of detecting MTB and simultaneously assessing rifampicin resistance within two hours (). In a study evaluating Xpert MTB/RIF accuracy for TBP and other forms of extrapulmonary TB, sensitivity was 63.8% with high specificity (100%) (). Furthermore, in high TB prevalence areas, IGRAs have limited utility for diagnosing active TB, as positive results only indicate prior MTB antigen exposure and do not reliably distinguish latent from active infection (). In the present case, the patient was initially misdiagnosed with TBP. Therefore, if patients fail to respond to appropriate anti-tuberculosis therapy, clinicians should consider the possibility of Nocardia infection and pursue microbiological identification and susceptibility testing promptly. In this case, the negative pericardial fluid Xpert MTB/RIF, cultures, and IGRA, combined with the lack of response to anti-tuberculosis therapy, definitively excluded TBP.
Methicillin-resistant Staphylococcus aureus (MRSA) pericarditis and pericardial abscesses are rare and typically associated with chronic comorbidities or prolonged healthcare exposure (, ). Pericardial effusion occurs in 94.9% of MRSA pericarditis cases, with cardiac tamponade developing in 83.8% (). In reported cases, MRSA is invariably isolated from pericardial fluid, and bacteremia is present in 64.1% (). The adult mortality rate is 20.5%, with median survival of 21.8 days, primarily due to multi-organ dysfunction from septic shock (). In this case, the patient lacked significant healthcare exposure or chronic comorbidities predisposing to MRSA, and both blood and pericardial fluid cultures were negative for MRSA. Consequently, MRSA was definitively excluded as the etiology.
In most reported cases of severe pericarditis or cardiac tamponade associated with influenza virus infection, Influenza A is the causative subtype (–). Isolated pericarditis (without concomitant myocarditis) is frequently associated with pericardial effusions (). Males and older patients are more likely to present with isolated pericarditis, whereas females and younger patients more commonly develop myopericarditis (). Patients of any age presenting with chest pain, tachycardia, and hemodynamic instability occurring within 2–4 weeks of influenza-like illness onset should be evaluated for cardiac involvement (pericarditis or myopericarditis) (). In this case, the patient presented with pericardial effusion but lacked other typical features such as recent influenza-like respiratory symptoms or chest pain, resulting in a low clinical suspicion for influenza-associated pericarditis.
Fungal pericarditis is rare. (1 → 3)-β-D-Glucan (BDG), a component of most fungal cell walls (except Cryptococcus and Mucorales), serves as a surrogate serum biomarker for diagnosing invasive fungal infections (IFIs) (–). BDG has been used in the diagnosis of IFIs, including Pneumocystis jirovecii pneumonia (PJP), cryptococcosis, and others, in people living with HIV (PLWH) (–46). Several studies evaluating serum BDG (using the Fungitell assay with varying diagnostic cutoffs) for PJP diagnosis in PLWH demonstrated sensitivities of 90%–100% and specificities of 61.3–96.4% (–46). However, for cryptococcosis diagnosis, BDG sensitivity in cerebrospinal fluid (CSF) is 89% (specificity 85%), whereas in serum, sensitivity is 79% (specificity 61%) (47). Currently, data on the sensitivity and specificity of serum BDG for diagnosing fungal pericarditis are lacking. In this case, the patient's serum BDG was negative. However, a fungal etiology could not be definitively excluded based on this result alone. Subsequently, culture of the pericardial fluid grew Nocardia species, with no fungal growth. The subsequent clinical response to Nocardia-directed antibiotic therapy, without antifungal agents, further supported Nocardia as the causative pathogen and and argued against a fungal etiology.
Microbiological identification remains the gold standard for diagnosing Nocardia pericarditis. However, in AIDS patients with negative initial pericardial fluid cultures and poor response to empirical therapy, extending the culture incubation period to at least 10 days is necessary to reduce the risk of false-negative results (). Notably, the diagnostic approach (e.g., prolonged culture) and therapeutic resources (e.g., comprehensive susceptibility testing) employed in this case may be challenging to implement in resource-limited settings. In such settings, clinicians should prioritize basic microbiological tests (Gram stain and partial acid-fast stain) to facilitate the early suspicion/detection of Nocardia and consider initiating empirical therapy with a regimen of TMP-SMZ combined with amikacin, even without species identification. Additionally, pericardiocentesis for diagnostic sampling and therapeutic drainage should be emphasized as a critical intervention, irrespective of available diagnostic resources. As summarized in Table 2, the constellation of fever, dyspnea, chest pain, and pericardial effusion, particularly if accompanied by the isolation of slow-growing, branching Gram-positive bacilli exhibiting partial acid-fastness from pericardial fluid, should raise strong suspicion for Nocardia infection.
Nocardia infections are characterized by potential for rapid progression and a propensity for relapse or recrudescence (). In this case, despite massive purulent pericardial effusion and rapid clinical deterioration, successful treatment relied on accurate microbiological identification, timely initiation of appropriate antibiotic therapy, and effective pericardiocentesis drainage.
Empirical antibiotic therapy should be initiated promptly when Nocardia infection is suspected. Trimethoprim-sulfamethoxazole (TMP-SMZ) is the established first-line agent for nocardiosis (48). Antimicrobial selection should consider factors including local epidemiology, clinical presentation (severity, sites of involvement), patient-specific factors (e.g., comorbidities, immunosuppression), antimicrobial susceptibility profiles, and potential adverse effects (, 49–51). For isolates resistant to sulfonamides or patients intolerant of TMP-SMZ, alternatives include high-dose TMP-SMZ (if tolerated), combination therapy, or other active agents such as carbapenems (imipenem, meropenem) or linezolid (52, 53). Immunocompromised patients typically require extended antimicrobial therapy (minimum 6–12 months) (48). Early diagnosis, prompt initiation of therapy, adequate dosing, and adherence to the prolonged treatment duration are essential for cure and preventing relapse.
The favorable clinical and radiological response observed in our patient following the initiation of appropriate Nocardia-directed therapy (initially ceftriaxone/amikacin, transitioning to long-term TMP-SMZ -based combination) underscores its efficacy. This case highlights the necessity of including Nocardia pericarditis in the differential diagnosis of immunosuppressed patients presenting with purulent pericarditis. Early identification, accurate diagnosis, prompt initiation of appropriate treatment, and effective management are critical for improving patient outcomes. Crucial management components include ensuring timely pericardial puncture for diagnosis and drainage, administering an extended course of antimicrobial therapy, and closely monitoring for potential drug-related adverse effects.
The primary limitation is the inability to identify the Nocardia isolate to the species level due to resource constraints, specifically the lack of access to molecular techniques such as 16S rRNA sequencing. This is clinically significant due to interspecies variations in antimicrobial susceptibility (, 54), which potentially compromise optimal therapy. Future studies and clinical practice should prioritize molecular identification for species-level diagnosis to enable species-directed therapy. Furthermore, as a single-center case report, the generalizability of our findings is limited. Multicenter studies with larger cohorts are needed to validate the proposed diagnostic and therapeutic approach.
Nocardia pericarditis is a rare but potentially fatal opportunistic infection that should be considered in the differential diagnosis of purulent pericarditis. Microbiological culture remains the diagnostic gold standard. Optimal outcomes require timely diagnosis, therapeutic pericardial drainage, and prolonged antimicrobial therapy.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
Ethics statement
Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
XZ: Methodology, Validation, Writing – original draft, Writing – review & editing. AL: Methodology, Validation, Writing – original draft, Writing – review & editing. FC: Supervision, Validation, Writing – review & editing. SJ: Data curation, Validation, Writing – review & editing. YR: Writing – review & editing, Data curation, Validation. SL: Validation, Writing – review & editing, Data curation. LZ: Data curation, Validation, Writing – review & editing. ZH: Writing – review & editing, Validation, Supervision. JL: Data curation, Validation, Visualization, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This research was funded by the Bureau of Science and Technology of Yulin (Grant No. 202432059).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
Brown-ElliottBABrownJMConvillePSWallaceRJ. Clinical and laboratory features of the Nocardia spp. Based on current molecular taxonomy. Clin Microbiol Rev. (2006) 19(2):259–82. 10.1128/CMR.19.2.259-282.2006
2.
TraxlerRMBellMELaskerBHeaddBShiehW-JMcQuistonJR. Updated review on Nocardia species: 2006–2021. Clin Microbiol Rev. (2022) 35(4):e0002721. 10.1128/cmr.00027-21
3.
SaubolleMASusslandD. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol. (2003) 41(10):4497–501. 10.1128/JCM.41.10.4497-4501.2003
4.
McNeilMMBrownJM. The medically important aerobic actinomycetes: epidemiology and microbiology. Clin Microbiol Rev. (1994) 7(3):357–417. 10.1128/CMR.7.3.357
5.
CoussementJLebeauxDvan DeldenCGuillotHFreundRMarbusSet alNocardia infection in solid organ transplant recipients: a multicenter European case-control study. Clin Infect Dis. (2016) 63(3):338–45. 10.1093/cid/ciw241
6.
HoltzHALaveryDPKapilaR. Actinomycetales infection in the acquired immunodeficiency syndrome. Ann Intern Med. (1985) 102(2):203–5. 10.7326/0003-4819-102-2-203
7.
LeangBLynenLLimKJacquesGVan EsbroeckMZolfoM. Disseminated nocardiosis presenting with cardiac tamponade in an HIV patient. Int J STD AIDS. (2004) 15(12):839–40. 10.1258/0956462042563620
8.
DumicIBrownAMageeKElwasilaSKaljevicMAnticMet alPrimary lymphocutaneous Nocardia brasiliensis in an immunocompetent host: case report and literature review. Medicina (Kaunas). (2022) 58(4):488. 10.3390/medicina58040488
9.
LernerPI. Nocardiosis. Clin Infect Dis. (1996) 22(6):891–905. 10.1093/clinids/22.6.891
10.
TomásRMVillanuevaRMCalzadaSRDurantezMSTarazonaJMVAlapontMMet alPulmonary nocardiosis: risk factors and outcomes. Respirology (Carlton, Vic). (2007) 12(3):394–400. 10.1111/j.1440-1843.2007.01078.x
11.
Garcia-BellmuntLSibilaOSolanesISanchez-ReusFPlazaV. Pulmonary nocardiosis in patients with COPD: characteristics and prognostic factors. Arch Bronconeumol (Engl Ed). (2012) 48(8):280–5. 10.1016/j.arbr.2012.06.006
12.
ChangP-LHsiehW-SChiangC-LTuohyMJHallGSProcopGWet alHo H-T: the hsp65 gene patterns of less common mycobacterium and Nocardia spp. by polymerase chain reaction-restriction fragment length polymorphism analysis with capillary electrophoresis. Diagn Microbiol Infect Dis. (2007) 58(3):315–23. 10.1016/j.diagmicrobio.2007.02.004
13.
ShawJAIrusenEMDiaconAHKoegelenbergCF. Pleural tuberculosis: a concise clinical review. Clin Respir J. (2018) 12(5):1779–86. 10.1111/crj.12900
14.
HuoZ-YPengL. Accuracy of the interferon-γ release assay for the diagnosis of active tuberculosis among HIV-seropositive individuals: a systematic review and meta-analysis. BMC Infect Dis. (2016) 16(1):350. 10.1186/s12879-016-1687-8
15.
WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. 2nd ed.Geneva: World Health Organization (2016).
16.
RatanjeeK-JJTaylorSKMarshallSLMarshallR. Nocardia asteroides peritoneal dialysis-related peritonitis: a case of successful treatment and return to peritoneal dialysis. Nephrol Dial Transplant. (2008) 23(8):2693–4. 10.1093/ndt/gfn252
17.
RamanathanPRahimiAR. Nocardia asteroides pericarditis in association with HIV. AIDS Patient Care STDS. (2000) 14(12):621–5. 10.1089/10872910050206531
18.
JinnoSJirakulapornTBankowskiMJKimWWongR. Rare case of Nocardia asteroides pericarditis in a human immunodeficiency virus-infected patient. J Clin Microbiol. (2007) 45(7):2330–3. 10.1128/JCM.00149-07
19.
AisenbergGMy MartinRME. Pericardial tamponade caused by Nocardia asteroides in a patient with acquired immunodeficiency syndrome: would sulfa prophylaxis have spared this infection?Infect Dis Clin Pract. (2014) 22(4):e34–6. 10.1097/IPC.0b013e31829104fe
20.
McKinneyWPSmithMRRobertsSAMorrisAJ. Species distribution and susceptibility of Nocardia isolates in New Zealand 2002–2021. Pathology. (2023) 55(5):680–7. 10.1016/j.pathol.2023.03.008
21.
NakaharaiKSakamotoYYaitaKYoshimuraYIgarashiSTachikawaN. Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score. Eur J Clin Pharmacol. (2016) 72(8):1003–11. 10.1007/s00228-016-2064-7
22.
ThiimMFriedmanLS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis. (2003) 7(2):381–99, vi-vii. 10.1016/s1089-3261(03)00021-7
23.
MistryRRawsonTMTroiseOMughalNMooreLSPHughesS. Haematological and hepatic adverse effects of ceftriaxone in ambulatory care: a dual-centre retrospective observational analysis of standard vs high dose. BMC Infect Dis. (2022) 22(1):959. 10.1186/s12879-022-07925-y
24.
ElajezRNisarSAdeliM. Does trimethoprim-sulfamethoxazole prophylaxis induce myelosuppression in primary immune deficiency disease patients; A retrospective, 3 groups comparative study. Asian Pac J Allergy Immunol. (2023) 41(4):353–60. 10.12932/AP-050320-0782
25.
RiveroAEsteveASantosJMárquezM. Cardiac tamponade caused by Nocardia asteroides in an HIV-infected patient. J Infect. (2000) 40(2):206–7. 10.1016/S0163-4453(00)80024-9
26.
ChandrashekarUKAcharyaVGnanadevNCVargheseGKChawlaK. Pulmonary nocardiosis presenting with cardiac tamponade and bilateral pleural effusion in a HIV patient. Trop Dr. (2009) 39(3):184–6. 10.1258/td.2008.080367
27.
GriesselRMittonBRuleRSaidM. A case report of Nocardia asiatica constrictive pericarditis in a patient with human immunodeficiency virus. Cardiovasc Pathol. (2022) 58:107403. 10.1016/j.carpath.2021.107403
28.
ImazioMGaitaFLeWinterM. Evaluation and treatment of pericarditis: a systematic review. JAMA. (2015) 314(14):1498–506. 10.1001/jama.2015.12763
29.
SpodickDH. Tuberculous pericarditis. AMA Arch Intern Med. (1956) 98(6):737–49. 10.1001/archinte.1956.00250300055008
30.
TheronGPeterJCalligaroGMeldauRHanrahanCKhalfeyHet alDeterminants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Sci Rep. (2014) 4(1):5658. 10.1038/srep05658
31.
KohliMSchillerIDendukuriNYaoMDhedaKDenkingerCMet alXpert MTB/RIF ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. (2021) 1(1):CD012768. 10.1002/14651858.CD012768.pub3
32.
PandieSPeterJGKerbelkerZSMeldauRGovenderTGNtsekheUet alDiagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-γ in a high burden setting: a prospective study. BMC Med. (2014) 12(1):101. 10.1186/1741-7015-12-101
33.
CattamanchiASmithRSteingartKRMetcalfeJZDateAColemanCet alInterferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. (2011) 56(3):230–8. 10.1097/QAI.0b013e31820b07ab
34.
LakhundiSZhangK. Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin Microbiol Rev. (2018) 31(4):e00020-18. 10.1128/CMR.00020-18
35.
RodvoldKAMcConeghyKW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis (2014) 58(Suppl 1):S20–7. 10.1093/cid/cit614
36.
RadovanovicMPetrovicMHannaRDNordstromCWCalvinADBarsoumMKet alClinical presentation and management of methicillin-resistant Staphylococcus aureus pericarditis-systematic review. J Cardiovasc Dev Dis. (2022) 9(4):103. 10.3390/jcdd9040103
37.
PandeyYHasanRJoshiKPHabashFJJaganaR. Acute influenza infection presenting with cardiac tamponade: a case report and review of literature. Perm J. (2019) 23(1):18–104. 10.7812/TPP/18-104
38.
SidhuRSSharmaAPatersonIDBaineyKR. Influenza H1N1 infection leading to cardiac tamponade in a previously healthy patient: a case report. Res Cardiovasc Med. (2016) 5(3):e31546. 10.5812/cardiovascmed.31546
39.
MartÃn-LázaroJFHomsCBenitoRPedroASSuárezMA. Chronic pericardial effusion secondary to a influenza virus A (H1N1)/2009 infection. Turk Kardiyol Dern Ars. (2013) 41(2):157–60. 10.5543/tkda.2013.18827
40.
RadovanovicMPetrovicMBarsoumMKNordstromCWCalvinADDumicIet alInfluenza myopericarditis and pericarditis: a literature review. J Clin Med. (2022) 11(14):4123. 10.3390/jcm11144123
41.
AmbastaACarsonJChurchDL. The use of biomarkers and molecular methods for the earlier diagnosis of invasive aspergillosis in immunocompromised patients. Med Mycol. (2015) 53(6):531–57. 10.1093/mmy/myv026
42.
HammarströmHStjärne AspelundAChristenssonBHeußelCPIsakssonJKondoriNet alProspective evaluation of a combination of fungal biomarkers for the diagnosis of invasive fungal disease in high-risk haematology patients. Mycoses. (2018) 61(9):623–32. 10.1111/myc.12773
43.
HopkeABrownAJPHallRAWheelerRT. Dynamic fungal cell wall architecture in stress adaptation and immune evasion. Trends Microbiol. (2018) 26(4):284–95. 10.1016/j.tim.2018.01.007
44.
EstevesFLeeCHde SousaBBaduraRSeringaMFernandesCet al(1–3)-beta-D-glucan in association with lactate dehydrogenase as biomarkers of pneumocystis pneumonia (PcP) in HIV-infected patients. Eur J Clin Microbiol Infect Dis. (2014) 33(7):1173–80. 10.1007/s10096-014-2054-6
45.
DesmetSVan WijngaerdenEMaertensJVerhaegenJVerbekenEDe MunterPet alSerum (1–3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol. (2009) 47(12):3871–4. 10.1128/JCM.01756-09
46.
PassosAIMDertkigilRPRamosMdCBusso-LopesAFTararanCRibeiroEOet alSerum markers as an aid in the diagnosis of pulmonary fungal infections in AIDS patients. Braz J Infect Dis. (2017) 21(6):606–12. 10.1016/j.bjid.2017.07.002
47.
RheinJBahrNCMorawskiBMSchutzCZhangYFinkelmanMet alDetection of high cerebrospinal fluid levels of (1 → 3)-β-d-glucan in cryptococcal meningitis. Open Forum Infect Dis. (2014) 1(3):ofu105. 10.1093/ofid/ofu105
48.
MehtaHHShamooY. Pathogenic Nocardia: a diverse genus of emerging pathogens or just poorly recognized?PLoS Pathog. (2020) 16(3):e1008280. 10.1371/journal.ppat.1008280
49.
WangHZhuYCuiQWuWLiGChenDet alEpidemiology and antimicrobial resistance profiles of the Nocardia Species in China, 2009 to 2021. Microbiol Spectr. (2022) 10(2):e0156021. 10.1128/spectrum.01560-21
50.
YetmarZAMartyPKClementJMirandaCWengenackNLBeamE. State-of-the-art review: modern approach to nocardiosis-diagnosis, management, and uncertainties. Clin Infect Dis. (2025) 80(4):e53–64. 10.1093/cid/ciae643
51.
MargalitILebeauxDTishlerOGoldbergEBisharaJYahavDet alHow do I manage nocardiosis?Clin Microbiol Infect. (2021) 27(4):550–8. 10.1016/j.cmi.2020.12.019
52.
WangH-KShengW-HHungC-CChenY-CLeeM-HLinWSet alClinical characteristics, microbiology, and outcomes for patients with lung and disseminated nocardiosis in a tertiary hospital. J Formosan Med Assoc. (2015) 114(8):742–9. 10.1016/j.jfma.2013.07.017
53.
HaussaireDFournierP-EDjiguibaKMoalVLegrisTPurgusRet alNocardiosis in the south of France over a 10-years period, 2004–2014. Int J Infect Dis. (2017) 57:13–20. 10.1016/j.ijid.2017.01.005
54.
LaksananunNSaleePKaewpoowatQ. Nocardia beijingensis pericarditis presenting with cardiac tamponade: a case report. Int J STD AIDS. (2018) 29(5):515–9. 10.1177/0956462417736986
Summary
Keywords
Nocardia, pericarditis, antibiotic therapy, pericardiocentesis, AIDS
Citation
Zhong X, Lin A, Cao F, Jiang S, Ruan Y, Li S, Zhong L, He Z and Luo J (2025) Purulent pericarditis caused by Nocardia: a case report and literature review. Front. Cardiovasc. Med. 12:1465047. doi: 10.3389/fcvm.2025.1465047
Received
18 July 2024
Accepted
26 August 2025
Published
05 September 2025
Volume
12 - 2025
Edited by
Junjie Xiao, Shanghai University, China
Reviewed by
Shipeng Wang, First Affiliated Hospital of Jilin University, China
Bhavik Thacker, Parul University, India
Wei Shang, Nanjing University, China
Updates
Copyright
© 2025 Zhong, Lin, Cao, Jiang, Ruan, Li, Zhong, He and Luo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhiyi He zhiyi-river@163.com Jian Luo 99682728@qq.com
†These authors have contributed equally to this work and share first authorship
‡ These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.